Direct C-11 functionalisation of anatoxin-a. Application to the synthesis of new ligand-based structural probes

Abstract

A variety of methods have been evaluated for the functionalisation of the C-11 methyl group of anatoxin-a. Reaction of N-Boc anatoxin-a 9 with PhI(OH)OTs (Koser’s reagent) represents the method of choice and gives the synthetically versatile α-tosyloxy ketone 10. This intermediate provides a convenient vehicle for the attachment of spacer units to C-11 via a thioether linkage which has been applied to the synthesis of the dansylated [N-(5-dimethylamino-1-naphthylsulfonyl)] anatoxin-a derivatives. Preliminary biological data relating to the α-thiomethyl anatoxin-a derivative 16 and the dansylated ligands, 25 and 26, are also reported.

References

1. J. P. Devlin, O. E. Edwards, P. R. Gorham, N. R. Hunter, R. K. Pike and B. Stavric, Can. J. Chem., 1977, 55, 1367.
2. B. Badio, H. M. Garraffo, T. F. Spande and J. W. Daly, Med. Chem. Res., 1994, 4, 440; T. F. Spande, H. M. Garraffo, M. W. Edwards, H. J. C. Yeh, L. Pannell and J. W. Daly, J. Am. Chem. Soc., 1992, 114, 3475 For the assignment of the absolute stereochemistry of 2, see S. R. Fletcher, R. Baker, M. S. Chambers, R. H. Herbert, S. C. Hobbs, S. R. Thomas, H. M. Verrier, A. P. Watt and R. G. Ball, J. Org. Chem., 1994, 59, 1771 For studies indicating 2 to be a nicotinic agonist, see B. Badio and J. W. Daly, Mol. Pharmacol., 1994, 45, 563; B. Badio, D. Shi, H. M. Garraffo and J. W. Daly, Drug. Dev. Res., 1995, 36, 46.
3. P. Thomas, M. Stephens, G. Wilkie, M. Amar, G. G. Lunt, P. Whiting, T. Gallagher, E. Pereira, M. Alkondon, E. X. Albuquerque and S. Wonnacott, J. Neurochem., 1993, 60, 2308; P. Thomas, P. A. Brough, T. Gallagher and S. Wonnacott, Drug Dev. Res., 1994, 31, 147.
4. For a review of synthetic approaches to anatoxin-a, see H. L. Mansell, Tetrahedron, 1996, 52, 6025 Also see P. J. Parsons, N. P. Camp, J. M. Underwood and D. M. Harvey, Tetrahedron, 1996, 52, 11 637.
5. For the most recent synthetic work directed towards epibatidine and analogues, see B. M. Trost and G. R. Cook, Tetrahedron Lett., 1996, 37, 7485; C. Szántay, Z. Kardos-Balogh, I. Moldvai, C. Szántay Jr., E. Temesvári-Major and G. Blaskó, Tetrahedron, 1996, 52, 11 053; C. Zhang and M. T. Trudell, J. Org. Chem., 1996, 61, 7189; J. R. Malpass, D. A. Hemmings and A. L. Wallis, Tetrahedron Lett., 1996, 37, 3911; D. Bai, R. Xu, G. Chu and X. Zhu, J. Org. Chem., 1996, 61, 4600.
6. M. W. Holladay, S. A. Lebold and N.-H. Lin, Drug Dev. Res., 1995, 35, 191.
7. (a) F. J. Sardina, M. H. Howard, M. Morningstar and H. Rapoport, J. Org. Chem., 1990, 55, 5025; (b) M. H. Howard, F. J. Sardina and H. Rapoport, J. Org. Chem., 1990, 55, 2829; (c) F. J. Sardina, M. H. Howard, A. M. P. Koskinen and H. Rapoport, J. Org. Chem., 1989, 54, 4654; (d) A. M. P. Koskinen and H. Rapoport, J. Med. Chem., 1985, 28, 1301; (e) J. S. Petersen, G. Fels and H. Rapoport, J. Am. Chem. Soc., 1984, 106, 4539; (f) J. S. Petersen, S. Töteberg-Kaulen and H. Rapoport, J. Org. Chem., 1984, 49, 2948.
8. For structure–activity relationships relating to anatoxin-a, see S. Wonnacott, S. Jackman, K. L. Swanson, H. Rapoport and E. X. Albuquerque, J. Pharmacol. Exp. Ther., 1991, 259, 387; K. L. Swanson, R. S. Aronstam, S. Wonnacott, H. Rapoport and E. X. Albuquerque, J. Pharmacol. Exp. Ther., 1991, 259, 377; K. L. Swanson, Y. Aracava, F. J. Sardina, H. Rapoport, R. S. Aronstam and E. X. Albuquerque, Mol. Pharmacol., 1989, 35, 233; K. L. Swanson, C. N. Allen, R. S. Aronstam, H. Rapoport and E. X. Albuquerque, Mol. Pharmacol., 1986, 29, 250 For computational studies aimed at the structure–activity relationships associated with anatoxin-a and derivatives, see D. T. Manallack, D. D. Ellis, P. E. Thompson, T. Gallagher and D. J. Livingstone, Nat. Prod. Lett., 1994, 4, 121; D. T. Manallack, T. Gallagher and D. J. Livingstone, in Neural Networks in QSAR and Drug Design, ed. J. Devillers, Academic Press, London, 1996, p. 177.
9. D. B. Kanne, D. J. Ashworth, M. T. Cheng, L. C. Mutter and L. G. Abood, J. Am. Chem. Soc., 1986, 108, 7864; D. B. Kanne and L. G. Abood, J. Med. Chem., 1988, 31, 506.
10. P. A. Brough, T. Gallagher, P. Thomas, S. Wonnacott, R. Baker, K. M. A. Malik and M. B. Hursthouse, J. Chem. Soc., Chem. Commun., 1992, 1087 For other studies focused on the biological significance of enone conformation, see: P. Thomson, D. T. Manallack, F. E. Blaney and T. Gallagher, J. Comput. Aided Mol. Des., 1992, 287; U. Hacksell and C. Mellin, Prog. Brain Res., 1989, 79, 95.
11. A. Hernandez and H. Rapoport, J. Org. Chem., 1994, 59, 1058.
12. For the application of dansylated acetylcholine derivatives, see: T. Heidmann and J. P. Changeux, Eur. J. Biochem., 1979, 94, 281; T. Heidmann and J. P. Changeux, Biochem. Biophys. Res. Commun., 1980, 97, 889.
13. P. Kofuji, Y. Aracava, K. L. Swanson, R. S. Aronstam, H. Rapoport and E. X. Albuquerque, J. Pharmacol. Exp. Ther., 1990, 252, 517; D. K. Stevens and R. I. Krieger, Toxicon, 1990, 28, 133 N,N-dimethylanatoxin-a has also been evaluated: A. C. S. Costa, K. L. Swanson, Y. Aracava, R. S. Aronstam and E. X. Albuquerque, J. Pharmacol. Exp. Ther., 1990, 252, 507.
14. N. J. S. Huby, P. Thompson, S. Wonnacott and T. Gallagher, J. Chem. Soc., Chem. Commun., 1991, 243.
15. S. Wonnacott, K. L. Swanson, E. X. Albuquerque, N. J. S. Huby, P. Thompson and T. Gallagher, Biochem. Pharmacol., 1992, 43, 419.
16. Homoanatoxin 6¹⁵ has also been isolated as a natural product: O. M. Skulberg, W. W. Carmichael, R. A. Anderson, S. Matsunaga, R. E. Moore and R. Skulberg, Environ. Toxicol. Chem., 1992, 11, 321.
17. G. F. Koser, A. G. Relenyi, A. N. Kalos, L. Rebrovic and R. H. Wettach, J. Org. Chem., 1982, 47, 2487.
18. P. A. Brough, PhD Thesis, University of Bristol, 1994.
19. N. Seiler, T. Schmidt-Glenewinkel and H. H. Schneider, J. Chromatogr., 1973, 84, 95.